About TRUEinvivo
TRUEinvivo is a company based in Guildford (United Kingdom) founded in 2014 by Shakar Jafari. TRUEinvivo has raised $1.24 million across 7 funding rounds. The company has 8 employees as of December 31, 2021. TRUEinvivo offers products and services including DOSEmapper1D™, DOSEmapper2D™, and DOSEmapper3D™. TRUEinvivo operates in a competitive market with competitors including Mirion, BrachyDOSE, LANDAUER, Medscint and Pure Luminescence Technologies, among others.
- Headquarter Guildford, United Kingdom
- Employees 8 as on 31 Dec, 2021
- Founders Shakar Jafari
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Trueinvivo Limited
- Date of Incorporation 02 Dec, 2014
- Jurisdiction GODALMING, SURREY
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.24 M (USD)
in 7 rounds
-
Latest Funding Round
$152.74 K (USD), Seed
Oct 18, 2023
-
Investors
Not available
-
Employee Count
8
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TRUEinvivo
TRUEinvivo offers a comprehensive portfolio of products and services, including DOSEmapper1D™, DOSEmapper2D™, and DOSEmapper3D™.
Measures tumor radiation dose with high resolution via catheter.
Flexible matrix for accurate radiation measurement in curved areas.
Spiral-wrapped system for mapping doses in organs at risk.
People of TRUEinvivo
Unlock access to complete
Unlock access to complete
Funding Insights of TRUEinvivo
TRUEinvivo has successfully raised a total of $1.24M across 7 strategic funding rounds. The most recent funding activity was a Seed round of $152.74 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by TRUEinvivo
Investment portfolio details for TRUEinvivo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TRUEinvivo
Detailed financials for TRUEinvivo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Trueinvivo Comparisons
Peer comparison for TRUEinvivo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TRUEinvivo
TRUEinvivo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mirion, BrachyDOSE, LANDAUER, Medscint and Pure Luminescence Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Radiation detection, measurement, analysis, and monitoring products are supplied.
|
|
| Locked | Locked | Locked |
System for precise radiation dose measurement in medical radiotherapy procedures.
|
|
| Locked | Locked | Locked |
Dosimetry equipment and services are provided for radiation exposure monitoring.
|
|
| Locked | Locked | Locked |
Offers advanced dosimetry tools for radiation measurements in medical applications.
|
|
| Locked | Locked | Locked |
Develops and manufactures synthetic hackmanite for luminescence, tenebrescence, and radiation-sensitive uses.
|
Detailed competitors of TRUEinvivo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Trueinvivo
Complete news archive for TRUEinvivo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TRUEinvivo
TRUEinvivo was founded in 2014 and raised its 1st funding round 4 years after it was founded.
TRUEinvivo is headquartered in Guildford, United Kingdom.
Nigel Biggs is the current CEO of TRUEinvivo.
TRUEinvivo is a funded company, having raised a total of $1.24M across 7 funding rounds to date.
As of Dec 31, 2021, the latest employee count at TRUEinvivo is 8.
TRUEinvivo was founded in 2014 in Guildford, United Kingdom, as a developer of medical devices in the radiotherapy sector. Micro silica bead array thermoluminescent detectors, known as DOSEmapper, are produced to measure radiation doses delivered to tumors during treatment. Operations focus on precision dosimetry tools for clinical applications, with the companys domain registered as trueinvivo.co.uk. Key personnel include founder Shakar Jafari and CEO Nigel Biggs.
TRUEinvivo's top competitors include Mirion, LANDAUER and BrachyDOSE.
TRUEinvivo offers DOSEmapper1D™, DOSEmapper2D™, and DOSEmapper3D™.